Nanoparticle delivery boosts AM1241 in mouse stroke injury

Polydopamine-modified mesoporous silica nanoparticles loaded with AM1241 alleviate cerebral ischemia-reperfusion injury.

Journal of biomaterials science. Polymer edition β€’ β€’ Highly Relevant
πŸ€–

AI Summary

This preclinical study asked whether packaging the selective CB2 receptor agonist AM1241 in polydopamine-modified mesoporous silica nanoparticles could improve treatment of cerebral ischemia-reperfusion injury. The researchers tested the formulation, called PMSNs@AM1241, in cell-based experiments and in mice. The nanoparticles were designed to cross the blood-brain barrier, release AM1241 in acidic conditions, and be taken up by microglia. The abstract does not report the sample size, comparator details, or treatment duration.

In cell studies, PMSNs@AM1241 showed biocompatibility, reduced reactive oxygen species, suppressed neuronal apoptosis, and dampened inflammatory signaling. In mice, the treatment reduced brain edema and infarct volume, limited tissue damage and neuronal apoptosis, and improved neurological deficits. The proposed mechanism involved the combined antioxidant activity of the nanoparticles and the anti-inflammatory activity of AM1241, including modulation of microglial states through CB2R activation and inhibition of the NF-ΞΊB pathway. The abstract provides no numerical effect sizes. This is an abstract-based summary of cell and animal research; it cannot establish whether the approach is safe or effective in humans, or whether it would provide a clinically meaningful benefit.

πŸ’‘ Key Findings

1
In a cell and mouse study, PMSNs@AM1241 reduced measures of cerebral ischemia-reperfusion injury, including brain edema, infarct volume, tissue damage, neuronal apoptosis, and neurological deficits.
Moderate
45%
2
The nanoparticle formulation crossed the blood-brain barrier and was taken up by microglia in vitro, while also showing reported biocompatibility and pH-responsive release of AM1241.
Moderate
40%
3
PMSNs@AM1241 suppressed oxidative stress and inflammatory responses, with effects linked to CB2R activation, reduced NF-ΞΊB signaling, and changes in M1-like and M2-like microglial markers.
Moderate
40%

πŸ“„ Original Abstract

Cerebral ischemia-reperfusion injury arises predominantly from excessive oxidative stress and sustained neuroinflammation. The selective cannabinoid receptor type 2 (CB2R) agonist AM1241 has shown potential to alleviate both pathological processes, yet its therapeutic efficacy is severely hampered by poor blood-brain barrier (BBB) permeability and inadequate intracerebral accumulation. To elevate the intracerebral therapeutic efficacy of AM1241, we constructed polydopamine-modified mesoporous silica nanoparticles (PMSNs) as nanocarriers to encapsulate AM1241, generating PMSNs@AM1241. Comprehensive physicochemical characterization confirmed that these nanoparticles exhibited uniform morphology, excellent dispersion, reliable storage stability, and pH-responsive drug release, enabling rapid AM1241 release in acidic environments. In vitro studies demonstrated that PMSNs@AM1241 exhibited high biocompatibility, could efficiently penetrate the blood-brain barrier, and were readily internalized by microglia. The nanomedicine effectively scavenged reactive oxygen species and suppressed neuronal apoptosis. It also inhibited the release of pro-inflammatory cytokines and reduced M1-like microglial marker expression while increasing M2-like marker expression via activation of CB2R and inhibition of the NF-ΞΊB signaling pathway, thereby exerting neuroprotective effects. In vivo, PMSNs@AM1241 significantly reduced brain edema, decreased infarct volume, attenuated histopathological damage, inhibited neuronal apoptosis, and markedly ameliorated neurological deficits in mice. Notably, the intrinsic antioxidant activity of PMSNs combined with the anti-inflammatory activity of AM1241 cooperatively modulated microglial inflammatory responses via the NF-ΞΊB signaling pathway, thereby attenuating oxidative stress and inflammatory cascades. Collectively, PMSNs@AM1241 represents an effective nanodelivery platform for cerebral ischemia-reperfusion injury, providing a novel strategy and experimental foundation.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.